AntidiabeticsSUBCUTANEOUSStandard
BASAGLAR
INSULIN GLARGINE
Standard Dose
300 UNITS/3ML (100 UNITS/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BASAGLAR is listed in Drugs@FDA under application 205692 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN GLARGINE Form and strength SOLUTION;SUBCUTANEOUS - 300 UNITS/3ML (100 UNITS/ML) Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2021-07-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview BASAGLAR is listed in Drugs@FDA under application 205692 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN GLARGINE Form and strength SOLUTION;SUBCUTANEOUS - 300 UNITS/3ML (100 UNITS/ML) Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2021-07-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.